Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study
NCT05900219
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
75
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-small-cell Lung Cancer
Interventions
DRUG:
HL-085+Vemurafenib
Sponsor
Shanghai Kechow Pharma, Inc.